Carson Wealth (CWM LLC)’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-36	Closed	-$4K	–	4642
2023 Q2	$4K	Hold	36	–	–	﹤0.01%	3589
2023 Q1	$3K	Hold	36	–	–	﹤0.01%	3595
2022 Q4	$1K	Hold	36	–	–	﹤0.01%	3920
2022 Q3	$1K	Buy	+36	New	+$998	﹤0.01%	3844
2022 Q1	–	Sell	-14	Closed	–	–	3977
2021 Q4	$0	Buy	+14	New	+$1.08K	﹤0.01%	3696

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Carson Wealth (CWM LLC)'s RETA Position: Q3 2023 in Review

Carson Wealth (CWM LLC) sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 36 shares — an estimated $4K sold.

Carson Wealth (CWM LLC) first reported a position in RETA in Q4 2021 and held it in 5 quarters. The position peaked at $4K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Carson Wealth (CWM LLC) reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Carson Wealth (CWM LLC) sold 36 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $4K.
Carson Wealth (CWM LLC) first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2021 and held it in 5 quarters.
Carson Wealth (CWM LLC)'s Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q3 2023, filed 11 Oct 2023.